BBT002, a tetravalent bispecific antibody targeting human IL-4Rα and IL-5, demonstrated enhanced efficacy over single-pathway targeting antibodies in an ovalbumin (OVA)-induced asthma mouse model

Tezspire (tezepelumab-ekko) - AstraZeneca, Amgen

BBT002 - Bambusa Therapeutics

Dupixent (dupilumab) - Sanofi, Regeneron

W. Liang; J. Jiang; T. Zhai; Y. Chen; S. Zhou; X. Zhang; W. Huang; T. Ho; S. Xu

May 30, 2026